Cellularis transforms breakthrough cellular science into life-changing therapies. We engineer living cells to target disease at its source, offering hope where traditional medicine falls short.
Engineered cells. Precision medicine.
Our proprietary platform harnesses the power of the human cell, reprogramming and enhancing it to fight disease with unprecedented precision.
We modify patient-derived cells with proprietary gene-editing tools to create targeted therapies that adapt to each individual's biology.
Our smart-cell platform ensures therapies reach their exact destination, minimising off-target effects and maximising therapeutic impact.
Machine learning models analyse millions of cell interactions to identify the most promising therapeutic candidates in a fraction of the time.
Where cells become cures
Our cell therapy programs span oncology, autoimmune disorders, and regenerative medicine.
CAR-T and next-generation cell therapies targeting solid tumours and haematological malignancies. Our lead programme CLS-401 has shown remarkable complete response rates in relapsed/refractory lymphoma.
Regulatory T-cell therapies designed to restore immune balance in conditions such as lupus, rheumatoid arthritis, and multiple sclerosis, without broad immunosuppression.
iPSC-derived cell therapies to regenerate damaged tissues in cardiac disease, spinal cord injury, and degenerative conditions. Rebuilding what was once thought irreparable.
Gene-corrected cell therapies for inherited metabolic disorders. Our platform enables rapid development of personalised treatments for ultra-rare conditions.
From lab to life
Our robust pipeline spans from early discovery through late-stage clinical development.
| Programme | Indication | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|
| CLS-401 | Relapsed Lymphoma | ||||
| CLS-205 | Solid Tumours (NSCLC) | ||||
| CLS-310 | Systemic Lupus | ||||
| CLS-112 | Cardiac Regeneration | ||||
| CLS-550 | Rare Metabolic Disorders |
Every cell tells a story. We're rewriting the ones that matter most.
Founded by a team of cell biologists, immunologists, and bioengineers, Cellularis was born from a singular belief: the human cell is the most powerful therapeutic tool ever discovered. We just need to learn how to use it.
Today, our team of over 300 scientists and clinicians across three continents is dedicated to making cell therapy accessible, affordable, and effective for patients who need it most.
Founded in Cambridge, MA
Scientists & clinicians worldwide
Total funding raised
Patents granted
Whether you're a clinician, researcher, patient advocate, or investor, we'd love to hear from you. Together, we can bring transformative cell therapies to those who need them.